<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04085016</url>
  </required_header>
  <id_info>
    <org_study_id>201610044RINB</org_study_id>
    <nct_id>NCT04085016</nct_id>
  </id_info>
  <brief_title>Effect of HMG-CoA Reductase Inhibitors on the Meibomian Gland Morphology in Patients With Meibomitis</brief_title>
  <official_title>Effect of HMG-CoA Reductase Inhibitors on the Meibomian Gland Morphology in Patients With Meibomitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study intends to evaluate the relationship between meibomitis and statin use. Meibomitis
      is the predominant cause of evaporative dry eye. Higher cholesterol levels were noted in
      patients with meibomitis when compared to controls without meibomitis. We would like to
      investigate the effect of statin use on meibomitis among patients with dyslipidemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of our study is to assess the change of meibomian gland structure in patients
      during treatment with 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitors
      using meibography. Patients with dyslipidemia with or without HMG-CoA reductase inhibitor
      (statin) treatment were recruited. Medical records are collected prospectively from Dec. 8th
      2016 to Dec. 31st 2019. Meibomian gland (MG) morphology described by meiboscores, lid margin
      abnormality scores, meibum quality, and dry eye parameters were compared between the two
      groups. This study may also provide information about possible treatment options in patients
      with meibomitis in the future.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 8, 2016</start_date>
  <completion_date type="Anticipated">May 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>change in meiboscore</measure>
    <time_frame>6 months</time_frame>
    <description>compare change in meibography images using meiboscore system</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Meibomian Gland Dysfunction</condition>
  <condition>Meibomitis</condition>
  <condition>Dyslipidemias</condition>
  <arm_group>
    <arm_group_label>meibography of statin group</arm_group_label>
    <description>patients with regular HMG CoA reductase inhibitor (statin) treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>meibography of non-statin group</arm_group_label>
    <description>patients with recently diagnosed dyslipidemia who were eligible to undergo 3 to 6 months of lifestyle interventions before re-evaluation for starting statin therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Keratograph 5M, Oculus, Wetzlar, Germany</intervention_name>
    <arm_group_label>meibography of non-statin group</arm_group_label>
    <arm_group_label>meibography of statin group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients with dyslipidemia
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with regular HMGCR inhibitor (statin) treatment, and those with recently
             diagnosed dyslipidemia who were eligible to undergo 3 to 6 months of lifestyle
             interventions before re-evaluation for starting statin therapy

        Exclusion Criteria:

          -  patients with active eye infection, previous history of chemical or thermal injury to
             ocular surface, previous operation history of eyelid or conjunctiva, any known allergy
             or contraindications to statins, history of percutaneous coronary intervention,
             cerevascular accident, acute coronary syndrome, or rheumatological diseases, fish oil
             supplements or pregnancy were excluded
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>I-Jong Wang, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>I-Jong Wang, MD,PhD</last_name>
    <phone>+886-23123456</phone>
    <email>ijong@ntu.edu.tw</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wu, MD</last_name>
    <email>p05421008@ntu.edu.tw</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>I-Jong Wang, MD, PhD</last_name>
      <phone>+886-23123456</phone>
      <email>ijong@ntu.edu.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Pinna A, Blasetti F, Zinellu A, Carru C, Solinas G. Meibomian gland dysfunction and hypercholesterolemia. Ophthalmology. 2013 Dec;120(12):2385-2389. doi: 10.1016/j.ophtha.2013.05.002. Epub 2013 Jun 6.</citation>
    <PMID>23747164</PMID>
  </reference>
  <reference>
    <citation>Nichols KK, Foulks GN, Bron AJ, Glasgow BJ, Dogru M, Tsubota K, Lemp MA, Sullivan DA. The international workshop on meibomian gland dysfunction: executive summary. Invest Ophthalmol Vis Sci. 2011 Mar 30;52(4):1922-9. doi: 10.1167/iovs.10-6997a. Review.</citation>
    <PMID>21450913</PMID>
  </reference>
  <reference>
    <citation>Finis D, Ackermann P, Pischel N, KÃ¶nig C, Hayajneh J, Borrelli M, Schrader S, Geerling G. Evaluation of Meibomian Gland Dysfunction and Local Distribution of Meibomian Gland Atrophy by Non-contact Infrared Meibography. Curr Eye Res. 2015;40(10):982-9. doi: 10.3109/02713683.2014.971929. Epub 2014 Oct 20.</citation>
    <PMID>25330304</PMID>
  </reference>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>September 8, 2019</study_first_submitted>
  <study_first_submitted_qc>September 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 11, 2019</study_first_posted>
  <last_update_submitted>September 8, 2019</last_update_submitted>
  <last_update_submitted_qc>September 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

